Ceftobiprole OATP1B interaction study

2024-518592-60-00 Protocol BPR-CP-101 Human pharmacology (Phase I) - Other Ended

Start 17 Jan 2025 · End 25 Feb 2025 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol BPR-CP-101

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 12
Countries 1
Sites 1

Community-acquired bacterial pneumonia

Key facts

Sponsor
Basilea Pharmaceutica International AG Allschwil
Participant type
Healthy volunteers
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Respiratory Tract Diseases [C08]
Trial duration
17 Jan 2025 → 25 Feb 2025
Decision date (initial)
2024-12-24
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Community-acquired bacterial pneumonia

VersionLevelCodeTermSystem organ class
20.0 PT 10035664 Pneumonia 100000004862

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Basilea Pharmaceutica International AG Allschwil

Sponsor organisation
Basilea Pharmaceutica International AG Allschwil
Address
Hegenheimermattweg 167b
City
Allschwil
Postcode
4123
Country
Switzerland

Scientific contact point

Organisation
Basilea Pharmaceutica International AG Allschwil
Contact name
Clinical Medical Lead

Public contact point

Organisation
Basilea Pharmaceutica International AG Allschwil
Contact name
Clinical Medical Lead

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Netherlands Ended 12 1
Rest of world 0

Investigational sites

Netherlands

1 site · Ended
Pharma Bio-Research Group
Program Management, Van Swietenlaan 6, 9728 NZ, Groningen

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Netherlands 2025-01-17 2025-02-25 2025-01-17 2025-01-27

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-11-04 Netherlands Acceptable
2024-12-24
2024-12-24